Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Sotagliflozin for T1D and Other ADCES Highlights
This episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, our second related to the Association of Diabetes Care and Education Specialists (ADCES) 2024 annual meeting, spotlights new data and perspectives from the meeting brought forth by pharmaceutical and diabetes technology companies.Check out our first episode related to ADCES 2024.A large theme of the episode is discussion around data and interactions with Lexicon, which announced the resubmission of a New Drug Application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.